This review focuses on the metabolism of a number of drugs, including MDMA and some related drugs (MDA, MDE, BDB, MBDB), amphetamines and selegiline. Clinical studies, case reports and studies in non-human animals (mostly rats) are referred to, with most data coming from rat studies. The focus of this paper appears to be that of pharmacokinetics rather than toxicokinetics. After examining these studies, the authors conclude that MDMA and similar drugs are metabolized via two overlapping pathways (O-demethylenation, D-alkyl side-chain degradation), with a third pathway hypothesized (aromatic hydroxylation). Relying on the studies of De la Torre and smaller samples studied by others, the review also concludes that variations in CYP2D6 function do not play a major role in MDMA metabolism or in MDMA toxicity in people. Previous findings indicate that other enzymes, such as CYP2B6, CYP1A2 and CYP3A4 may have a role in the metabolism of MDMA. Probable non-linear pharmacokinetics of MDMA in clinical trials are discussed. Catechol-O-methyltransferase (COMT) is hypothesized as playing some role in the metabolism of MDMA and related drugs because this enzyme also metabolizes catechols. There are also sections addressing metabolism of the other drugs listed in the title.